# EDGAR Filing Document

**Accession Number:** 0001854270
**File Stem:** 0001193125-26-177623
**Filing Date:** 2026-4
**Character Count:** 9024
**Document Hash:** 6e5c02a589703a5435a715c7e75a57ae
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-177623.hdr.sgml**: 20260424

**ACCESSION NUMBER**: 0001193125-26-177623

**CONFORMED SUBMISSION TYPE**: S-8 POS

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20260424

**DATE AS OF CHANGE**: 20260424

**EFFECTIVENESS DATE**: 20260424

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Senti Biosciences, Inc.
- **CENTRAL INDEX KEY:** 0001854270
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 862437900
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8 POS
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-276459
- **FILM NUMBER:** 26895616

**BUSINESS ADDRESS:**
- **STREET 1:** 2 CORPORATE DRIVE, FIRST FLOOR
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080
- **BUSINESS PHONE:** (650) 239-2030

**MAIL ADDRESS:**
- **STREET 1:** 2 CORPORATE DRIVE, FIRST FLOOR
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Senti Biosciences, Inc.\
- **DATE OF NAME CHANGE:** 20220615

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Dynamics Special Purpose Corp.
- **DATE OF NAME CHANGE:** 20210331

**As filed with the Securities and Exchange Commission on April 24, 2026** 

**Registration No. 333-285655** 

**Registration No. 333-276459** 

**Registration No. 333-269816** 

**Registration No. 333-266958** 

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549** 

**POST-EFFECTIVE AMENDMENT NO. 1 TO** 

**FORM S-8 (No. 333-285655)** 

**POST-EFFECTIVE AMENDMENT NO. 1 TO** 

**FORM S-8 (No. 333-276459)** 

**POST-EFFECTIVE AMENDMENT NO. 1 TO** 

**FORM S-8 (No. 333-269816)** 

**POST-EFFECTIVE AMENDMENT NO. 1 TO** 

**FORM S-8 (No. 333-266958)** 

**REGISTRATION STATEMENT** 

***UNDER***

***THE SECURITIES ACT OF 1933***

## SENTI BIOSCIENCES HOLDINGS, INC.
**(Exact name of registrant as specified in its charter)** 

---

| | | |
|:---|:---|:---|
| **Delaware**<br> **(State or other jurisdiction of**<br> **incorporation)** | **2 Corporate Drive, First Floor**<br> **South San Francisco, CA 94080**<br> **Telephone: (650) 382-3281** | **42-1912154**<br> **(IRS Employer**<br> **Identification No.)** |

---

**Senti Biosciences, Inc. Amended and Restated 2022 Equity Incentive Plan** 

**Senti Biosciences, Inc. Amended and Restated 2016 Stock Incentive Plan** 

**Senti Biosciences, Inc. 2022 Employee Stock Purchase Plan** 

**Senti Biosciences, Inc. Amended and Restated 2022 Inducement Plan** 

**(Full title of the plans)** 

**Timothy Lu, M.D., Ph.D** 

**Chief Executive Officer** 

**Senti Biosciences Holdings, Inc.** 

**2 Corporate Drive, First Floor** 

**South San Francisco, CA 94080** 

**Telephone: (650) 239-2030** 

**(Name, address, including zip code, and telephone number, including area code, of agent for service)** 

***Copies to:***

**Kirt W Shuldberg, Esq.** 

**Keith J. Scherer, Esq.** 

**Gunderson Dettmer Stough Villeneuve** 

**Franklin & Hachigian, LLP** 

**3570 Carmel Mountain Rd., Suite 200** 

**San Diego, California 92130** 

**(858) 436-8000** 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ☐ | Accelerated filer | ☐ |
| Non-accelerated filer | ☒ | Smaller reporting company | ☒ |
|  |  | Emerging growth company | ☒ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☒

------

**DEREGISTRATION OF SECURITIES** 

These Post-Effective Amendments (the "Post-Effective Amendments") relate to the Registration Statements on Form S-8 listed below (collectively, the "Registration Statements") filed with the Securities and Exchange Commission (the "Commission") by Senti Biosciences, Inc. ("Senti") and are being filed to deregister all securities that were registered for issuance on the Registration Statements and remain unissued or unsold thereunder.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Registration Statement No. [333-285655](http://www.sec.gov/Archives/edgar/data/1854270/000114036125007659/ef20045051_s8.htm) , as filed with the Commission on March 7, 2025, pertaining to the registration of securities
issuable under the Senti Biosciences, Inc. Amended and Restated 2022 Equity Incentive Plan (the "2022 Incentive Plan"), Senti Biosciences, Inc. 2022 Employee Stock Purchase Plan (the "ESPP") and Senti Biosciences, Inc. 2022
Amended and Restated Inducement Plan (the "Inducement Plan");

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Registration Statements No. [333-276459](http://www.sec.gov/Archives/edgar/data/1854270/000185427024000008/a20240110s-8.htm) and No. [333-269816](http://www.sec.gov/Archives/edgar/data/1854270/000185427023000024/a20230215s-8.htm) , as filed with the Commission on January 10, 2024 and February 15, 2023, respectively, each
pertaining to the registration of securities issuable under the 2022 Incentive Plan and the ESPP; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Registration Statement No. [333-266958](http://www.sec.gov/Archives/edgar/data/1854270/000185427022000023/a081622s-8doc.htm) , as filed with the Commission on August 18, 2022, pertaining to the registration of securities
issuable under the 2022 Incentive Plan, the ESPP, the Inducement Plan and the Senti Biosciences, Inc. Amended and Restated 2016 Stock Incentive Plan (the "2016 Incentive Plan", and collectively with the 2022 Incentive Plan, the ESPP and
the Inducement Plan, the "Plans").

On April 24, 2026, Senti completed a holding company reorganization (the "Reorganization"), whereby Senti became a direct wholly owned subsidiary of Senti Holdings, Inc., a Delaware corporation ("Senti Holdings"), which is a direct wholly owned subsidiary of Senti Biosciences Holdings, Inc., a Delaware corporation ("Senti Biosciences Holdings"). The Reorganization was completed pursuant to an Agreement and Plan of Merger, dated April 24, 2026 (the "Merger Agreement"), among Senti, Senti Biosciences Holdings and Senti Biosciences Merger Sub, Inc., a Delaware corporation ("Merger Sub"). In accordance with the Merger Agreement, the Reorganization was implemented pursuant to Section 251(g) of the Delaware General Corporation Law by the merger of Merger Sub with Senti, with Senti surviving the merger as a direct, wholly owned subsidiary of Senti Holdings, which is a direct, wholly owned subsidiary of Senti Biosciences Holdings (the "Merger"). At the effective time of the Merger, each outstanding share of the Senti's common stock, par value $0.0001 per share ("Senti Common Stock") was automatically converted in the Merger into one share of Senti Biosciences Holdings common stock, par value $0.0001 per share, evidencing the same proportional interests in Senti Biosciences Holdings and having the same designation, rights, powers, and preferences, and qualifications, limitations, and restrictions as a share of Senti Common Stock immediately prior to the Merger. Senti Biosciences Holdings is deemed to be the successor issuer of Senti under Rule 12g-3(a) of the Securities Exchange Act of 1934, as amended.

As a result of the Reorganization and in accordance with an undertaking made by Senti in the Registration Statements to remove from registration, by means of a post-effective amendment, any of the securities which remain unsold at the termination of the offering, Senti hereby removes from registration all of the securities registered under the Registration Statements which are issuable pursuant to the Plans and remain unsold as of the date hereof.

------

**SIGNATURES** 

Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused these post-effective amendments to the Registration Statements to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of South San Francisco, CA on the 24th day of April, 2026.

---

| | |
|:---|:---|
| **SENTI BIOSCIENCES HOLDINGS, INC.** | **SENTI BIOSCIENCES HOLDINGS, INC.** |
| By: | /s/ Timothy Lu |
| Name: | Timothy Lu, M.D., Ph.D. |
| Title: | Chief Executive Officer (Principal Executive Officer) |

---

No other person is required to sign these Post-Effective Amendments in reliance upon Rule 478 under the Securities Act of 1933, as amended.